BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-4508 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-4508\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07003321-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07003321)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Ce
 ll Lung Cancer\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/hrs-4508#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07003321
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4508: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:HRS-4508\, phase 1/2.\nStudy: A Study of HRS-4508 in Combinatio
 n With Other Anti-tumor Therapy for Solid Tumor\nEstimated primary complet
 ion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hr
 s-4508#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07140393
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-4508\, phase 1/2.\nStudy: A Trial of HRS-6209 in Combinatio
 n With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as 
 Monotherapy in Patients With Advanced Solid Tumors\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hrs-4508#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06555068
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232849-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07232849)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hrs-4508#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232849
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598735-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:HRS-4508: Phase 1 readout est. (NCT06598735)
DESCRIPTION:HRS-4508\, phase 1.\nStudy: A Clinical Study of the Safety\, To
 lerability\, Pharmacokinetics\, and Initial Efficacy of HRS-4508 Monothera
 py in Patients With Advanced or Metastatic Solid Tumors\nEstimated primary
  completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/hrs-4508#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06598735
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2130@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 2 readout est. (NCT05582499)
DESCRIPTION:HRS-4508\, phase 2.\nStudy: Fudan University Shanghai Cancer Ce
 nter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hrs-4508#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
